Significant tumor growth delay from talazoparib treatment was seen with parental HT1080 tumors (Fig. 2K), consistent with prior work, but this effect was lost in REV7 KO tumors (HT1080, P = 0.0092 versus REV7 KO, P = 0.9926) (Fig. 2L). Here, MAD2L2 is linked to neoplasm.